Nano-anticancer promise in Phase II ovarian cancer trial
This article was originally published in Scrip
Executive Summary
CRLX101, Cerulean Pharma's investigational 'nanopharmaceutical' has met its primary efficacy endpoint in an ongoing single-arm Phase II monotherapy trial in relapsed ovarian cancer.